Allergen-specific Immunoglobulin E antibodies against cow's milk proteins (CM-sIgE)

Allergen-specific Immunoglobulin E (IgE) antibodies against cow's milk proteins are the primary mediators of Type I hypersensitivity reactions in cow's milk allergy (CMA). These antibodies are produced by B cells following sensitization to specific milk proteins, primarily caseins (Bos d 8) and whey proteins such as alpha-lactalbumin (Bos d 4) and beta-lactoglobulin (Bos d 5). Once produced, these specific IgE molecules circulate and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to cow's milk allergens, the proteins cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes. This process leads to clinical symptoms ranging from mild urticaria to life-threatening anaphylaxis. Therapeutic interventions, such as the monoclonal antibody omalizumab, target these antibodies by neutralizing free IgE and downregulating its receptors, thereby increasing the threshold for allergic reactions and facilitating safer oral immunotherapy.

Other names

Cow's milk-specific IgEMilk-specific IgEsIgE to cow's milkIgE against Bos d 4IgE against Bos d 5IgE against Bos d 8

Neutralization of free serum IgE to prevent binding to FcεRI receptors on mast cells and basophils, and subsequent downregulation of these receptors to reduce cellular sensitivity to allergens.